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Cancer is one of leading ailments in which abnormal cells grow
and can occur in all the living cells at every stage of human life.
Many of peoples are suffering from cancer disease in the globe
(Rashid et al., 2015). Chemotherapy is considered as one of the
important treatments against the cancer diseases. Nowadays,
many researchers are interested to find anti neoplastic drugs
with less harmful effects on the immune system.
On the other hand, Diabetes is a clinical syndrome charac-
terized by high levels of blood glucose resulting as defects in
insulin production, insulin action, or both. Type 2 diabetesmellitus is the fastest rising worldwide threat to public health.
The diabetic cases were 171 million in 2000 and may be found
to increase to 366 million in 2030 (Narender et al., 2013).
a-Amylase and a-glycosidase are important enzymes involved
in carbohydrates breakdown and intestinal absorption. Acar-
bose, miglitol, and voglibose are good synthetic antidiabetic
agents but, usage of those can be reduced may induce side
effects such as flatulence, abdominal cramps, vomiting, and
diarrhoea. Because of a number new drugs are developed by
the researcher, which induces no harmful side effects.
Recently, the oxadiazole chemistry has been developed
extensively and is still developing. Most of the drugs are used
clinically, which comprise oxadiazole moiety in association
with various heterocyclic rings. 1,3,4-Oxadiazoles are impor-
tant heterocyclic compounds, which are synthetically useful,
and biologically active. Literature survey revealed that 1,3,4
oxadiazoles are related to a wide range of pharmacological
activities. 2,5 Substituted oxadiazole derivatives have been
reported to possess anticonvulsant activity and antifungal
activity (Zhang et al., 2013). Oxadiazole moiety is also useds. Saudi
2 S. Kavitha et al.in material science in the field of photo sensitizer and liquid
crystals and also a number of biological properties have been
described: anticancer (Bondock et al., 2012; Salahuddin
et al., 2014), antimicrobial (Aziz-ur-Rehman et al., 2015;
Desai et al., 2011; Malladi et al., 2014), anti-inflammatory
(Gadegoni and Manda, 2013), anticonvulsant (Harish et al.,
2013), antioxidant (Musad et al., 2011), Anti-HIV
(Hajimahdi et al., 2013), etc.
Keeping the view of this, we have synthesized 15 novel new
oxadiazole derivatives carrying urea, amide, and sulphona-
mide groups to investigate their antidiabetic and anti-
inflammatory. Further, we tested 1,3,4-oxadiazole derivatives
against HeLa (cervical) and MCF-7 (breast) cancer cell lines
using MTT assay.ONO2
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2.1. General
New synthetic approach for a novel series of 2,5 disubstituted
1,3,4-oxadiazole derivatives bearing urea, amide, sulphona-
mide is shown in Scheme 1. The starting material 2-cyclo
hexyl-5-phenyl-1,3,4-oxadiazole was obtained by the reaction
of cyclohexanoic acid with Benzohydrazide in POCl3. The
nitration reaction was carried out for 3 using KNO3 and
Con H2SO4 afforded 2-cyclohexyl-5-(3-nitrophenyl)-1,3,4-oxa
diazole in 72% yield. The nitro compound (4) was changed
to amine as parent compound (5) through tin chloride and
Con HCl at room temperature. The desired 2,5 disubstituted
1,3,4 oxadiazole derivatives were bearing urea and amide,
and sulphonamide functionalities were synthesized by reacting
parent compound (5) with aryl isocyanates, acids, and aryl
sulphonyl chloride respectively at rt with mild conditions.
The purity of synthetic compounds was checked by TLC andPlease cite this article in press as: Kavitha, S. et al., Synthesis, characterization and b
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structures.
2.2. Chemicals
All the chemical reagents and solvents of analytical grade were
purchased from the local supplier and Sigma Aldrich. Silica-
coated TLC plates were used with petroleum ether and Ethyl
acetate as the solvent system. 1H NMR spectra were recorded
by utilizing 400 and 300 MHz Bruker spectrometers indicating
chemical shift value on ppm scale and TMS was taken as an
internal reference. Perkin Elmer RXI was utilized for IR spec-
tra by using KBr pellet method. Thermo LCQ Deca XP MAX
spectrometer was utilized for mass spectra. The thin layerchromatography (TLC) analysis was carried out for synthesis
using 5  20 cm plate coated with silica gel GF254.
2.3. Synthesis of 2-cyclohexyl-5-phenyl-1,3,4-oxadiazole
2-Cyclohexyl-5-phenyl-1,3,4-oxadiazole was synthesized
according to the procedure by Chandrakantha et al. (2010)
with minor modification. An equimolar mixture of Benzohy-
drazide with cyclohexanoic acid was refluxed with phospho-
rous oxychloride (7 vol) at 110 C for 2–3 h. The reaction
mixture was distilled off, the residue was quenched with ice
water, and the solid was separated, filtered off, and washed
with water repeatedly. Toluene was added to the mixture
and it was concentrated through rotovap to afford the product
as white solid.
M.p. 102 C; Yield 83%. IR (KBr, cm1): 2933, 2855 (CH2
Str), 1590 (C‚N), 1506, 1496, 1442 (for oxadiazole), 1018
(CAOAC). 1H NMR (CDCl3, 400 MHz): d 1.24–1.46 (m,
3H), 1.62–1.72 (m, 3H), 1.86–1.93 (m, 2H), 2.13–2.18 (m,
2H), 2.93–3.01 (m, 1H), 7.45–7.49 (m, 3H), 7.92 (d, 2H,
J= 8.1 Hz). 13NMR (CDCl3 300 MHz); d 170, 164.3, 131.3,
128.9, 126.7, 124.2, 35.2, 30.1, 29.2, 25.4. LC/ESI-MS: m/z
value 229 (M+1).iological evaluation of novel 2,5 substituted-1,3,4 oxadiazole derivatives. Saudi
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Scheme 1 Synthesis of 2,5- substituted 1,3,4- Oxadiazole derivatives.
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oxadiazole
Concentrated sulphuric acid (5 mL, 26 N) was taken into a
flask at 0 C. 2-Cyclohexyl-5-phenyl-1,3,4-oxadiazole (1 mmol)
was added dropwise to the flask while stirring. To this cold
solution of Potassium nitrate (16 mmol) in concentrated sul-
phuric acid was added. The mixture was stirred for 30 min at
0 C and further for 1 h at room temperature. The reaction
progress was monitored by TLC (Petroleum ether and ethyl
acetate 8:2). The reaction mixture was quenched with ice water
and extracted using ethyl acetate, washed with water, 10%
NaHCO3, brine water and dried over sodium sulphate. The
organic mixture was concentrated and purified by silica col-
umn chromatography to afford nitro compound as light yel-
low solid. M.p. 74 C; Yield 65%.
IR (KBr, cm1): 2935, 2856 (CH2 Str), 1590 (C‚N), 1531
(ArANO2), 1515, 1486, 1441 (for oxadiazole), 1016 (CAOAC).
(1H NMR, CDCl3, 400 MHz): d 1.33–1.50 (m, 3H), 1.66–1.79
(m, 3H), 1.87–1.92 (m, 2H), 2.14–2.19 (m, 2H), 2.99–3.07 (m,
1H), 7.73 (t, 2H, J= 8.4 Hz), 8.37–8.43 (m, 1H) 8.84 (t, 1H,
J= 1.6 Hz). 13NMR (CDCl3 400 MHz); d 170.8, 162.5,
148.6, 132.3, 130.2, 127.6, 125.8, 124.2, 35.3, 30.1, 29.1, 25.4.
LC/ESI-MS: m/z value 274 (M+1).
2.5. Synthesis of 3-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl
amine
2-Cyclohexyl-5-(3-nitrophenyl)-1,3,4-oxadiazole (1 Equi) was
taken in a round bottom flask. Concentrated hydrochloric acid
(4 vol) and tin chloride (4 Equi) were added in portionwise.
The reaction was carried out for one hour at room temperature
with calcium chloride tube. The reaction mixture was pouredPlease cite this article in press as: Kavitha, S. et al., Synthesis, characterization and b
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mixture was extracted with ethyl acetate, washed with water,
NaHCO3 and brine water and dried over sodium sulphate.
The mixture was purified by silica column chromatography
to afford amino compound as light yellow solid. M.p; 118 C
Yield 69%. IR (KBr, cm1): 3440, 3362 (NH Stretch), 2927,
2856 (CH2 Str), 1597 (C‚N), 1564, 1469, 1412 (for oxadia-
zole), 1076 (CAOAC).
1H NMR (CDCl3, 400 MHz): d 1.27–1.36 (m, 2H), 1.41–
1.48 (m, 2H), 1.63–1.76 (m, 2H), 1.84–1.90 (m, 2H), 2.13–
2.18 (m, 2H), 2.94–3.01 (m, 1H), 3.82 (s, 2H), 6.80 (dd, 1H,
J= 2.2 Hz), 6.82 (dd, 1H, J= 2.2 Hz), 7.40 (t, 1H,
J = 1.2 Hz), 7.37 (dt, 1H). 13NMR (CDCl3 400 MHz); d
169.8, 164.5, 146.8, 129.9, 125, 117.9, 116.8, 112.7, 35.2, 30.1,
25.5, 27.4. LC/ESI-MS: m/z value 244 (M+1).
2.5.1. General procedure for the synthesis of urea derivatives
Amine (1 Equi) was taken in dichloromethane (10 mL) at
room temperature and added the substituted aromatic iso-
cyanates (1 Equiv) at 0 C. Then, the reaction mixture was
allowed to room temperature for 1–2 h. The reaction progress
was checked by TLC in petroleum ether and ethyl acetate (6:4).
The resulting organic mixture was concentrated under reduced
pressure to afford the product, which was purified by washing
with petroleum ether (Toche and Janrao, 2015).
2.5.2. General procedure for the synthesis of amide derivatives
To the solution of amine (1 Equiv), aromatic or aliphatic acids
(1.2 Equiv), HOBt (1 Equi) in dichloro methane was added
EDCI. HCl at 0 C. Then, triethylamine (4 Equiv) was added
dropwise and kept overnight at room temperature. The pro-
duct was diluted with ethyl acetate, washed with water, 2 N
HCl, 5% NaHCO3, and brine water, dried over anhydrousiological evaluation of novel 2,5 substituted-1,3,4 oxadiazole derivatives. Saudi
4 S. Kavitha et al.Na2SO4 and concentrated by the rotary evaporator to get resi-
due as solid.
2.5.3. General procedure for the synthesis of sulphonamide
derivatives
To a solution of amine (1 Equi) dichloro methane was added
to pyridine (4 Equi) followed by aromatic sulphonyl chloride
(1 Equi) added dropwise at 0 C. The reaction mixture was
gradually brought to room temperature, and stirred for 2 h.
The mixture was diluted with ethyl acetate, and washed with
water, 2 N HCl, 10% NaHCO3, brine water, and dried over
sodium sulphate. It was concentrated by rotary evaporator
to obtain sulphonamide as product (Toche and Janrao, 2015;
Dogruer et al., 2010).
2.5.4. Spectral data of synthesized compounds
2.5.4.1. 1-[3-(5-Cyclohexyl-[1,3,4] oxadiazol-2-yl)-phenyl]-3-
(4-fluoro-phenyl)-urea (6a). Yield 81%, M.p. 121; IR (KBr,
cm1) 2933, 2856 (CH2 Str), 1698 (C‚O), 3344 (NH), 1300
(CAF), 3058 (CH), 1560 (C‚N), 1033 (CAOAC), 1H NMR
(400 MHz, CDCl3) d ppm: 1.33–1.46 (m, 3H), 1.54–1.67 (m,
3H), 1.74–1.78 (m, 2H), 2.04–2.080 (dd, 2H), 2.99–3.06 (m,
1H), 7.14–7.09 (m, 2H), 7.45–7.49 (m, 1H), 7.58–7.54 (m,
1H), 8.23 (s, 1H), 8.73 (s, 1H), 8.98 (s, 1H).
13C NMR (400 MHz, CDCl3) d ppm; 169.4, 163.6, 158.6,
156.2, 152.5, 140.5, 135.7, 129.8, 124.0, 121.1, 120.2, 119.5,
115.3, 34.1, 29.5, 25.1, 24.6. LC/ESI-MS: m/z value; 381.1
(M+1).
2.5.4.2. 1-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-3-
p-tolyl-urea (6b). Yield 85%. M.p 185; IR (KBr, cm1)
2930, 2851 (CH2 Str), 1647 (NHAC‚O), 3321 (NH), 3039
(CH Str), 1414 (C‚N), 1037 (CAOAC). 1H NMR
(300 MHz, CDCl3) d ppm: 1.20–1.41 (m, 4H), 1.56–1.68 (m,
2H), 1.80–1.86 (m, 2H), 2.01–2.12 (m, 2H), 2.65 (s, 3H),
2.88–2.98 (m, 1H), 6.59–6.6 (m, 2H), 6.64 (t, 1H,
J= 2.4 Hz), 6.95 (s, 1H), 7.07 (t, 1H, J= 7.8 Hz), 7.37 (d,
1H, J= 8.1 Hz), 8.07 (dd, 1H, J= 7.8 Hz), 8.53 (d, 1H,
J= 1.5 Hz). 13C NMR (300 MHz, CDCl3) d ppm: 169.6,
164.1, 152.8, 140.2, 136.2, 131.7, 129.2, 129, 124.2, 121.1,
119.9, 111.8, 116, 39.4, 34.9, 29.8, 25, 20.4. LC/ESI-MS: m/z
value; 377 (M+1).
2.5.4.3. 1-[3-(5-Cyclohexyl-[1,3,4] oxadiazol-2-yl)-phenyl]-3-
(3-methoxy-phenyl)-urea (6c). Yield 78%, M.p 156, IR (KBr,
cm1): 2931, 2854 (CH2 Str), 1703 (NHAC‚O), 3339 (NH),
3089 (CH Ar), 1472 (C‚N), 1040 (CAOAC). 1H NMR
(300 MHz, CDCl3) d ppm: 1.18–1.42 (m, 4H), 1.64–1.70 (m,
2H), 1.77–1.82 (m, 2H), 2.05–2.11 (d, 2H), 2.92–3.02 (m,
1H), 3.72 (s, 3H), 6.54 (dd, 1H, J= 9 Hz), 6.92 (d, 1H,
J= 8.1 Hz), 7.16 (d, 1H, J= 1.2 Hz) 7.17–7.19 (m, 1H),
7.36 (t, 1H J= 8.1 Hz), 7.50 (d, 1H J= 8.1 Hz), 7.9 (s, 1H),
8.05 (d, 1H, J= 7.2 Hz), 8.32 (s, 1H) 8.66 (s, 1H). 13C
NMR (300 MHz, CDCl3) d ppm: 170.5, 164.7, 160.2, 153.5,
140.1, 139.7, 129.6, 123.9, 123.6, 121, 117.2, 112.3, 108.9,
105.9, 55.2, 35.4, 30.2, 27.3, 25.4. LC/ESI-MS: m/z value;
393 (M+1).
2.5.4.4. 4-Chloro-N-[3-(5-cyclohexyl-[1,3,4]oxadiazol-2-yl)-
phenyl]-benzamide (7a). Yield 79%, M.p 143, IR (KBr,
cm1); 2923, 2854 (CH2 Str), 1646 (C‚O), 3281 (NH), 3089Please cite this article in press as: Kavitha, S. et al., Synthesis, characterization and b
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.07.004(CH), 1472 (C‚N), 1095 (CAOAC), 727 (CACl). 1H NMR
(300 MHz, CDCl3) d ppm: 1.32–1.37 (m, 3H), 1.60–1.77 (m,
3H), 1.78–1.81 (m, 2H), 2.03–2.07 (d, 2H), 2.82–2.92 (m,
1H), 7.40–7.44 (m, 2H), 7.47 (s, 1H), 7.74 (s, 1H), 7.76–7.81
(m, 2H), 7.92 (d, 1H, J= 8.4 Hz), 8.11 (s, 1H), 8.21 (s, 1H).
13C NMR (400 MHz, CDCl3) d ppm; 169.6, 165, 163.9,
139.3, 137.4, 132.9, 129.1, 128.1, 124, 123.2, 121.8, 118.3,
39.7, 34.8, 29.7, 26.6, 24.9. LC/ESI-MS: m/z value; 382 (M
+1).
2.5.4.5. N-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-4-
methyl-benzamide (7b). Yield 58%, M.p 188, IR (KBr, cm1);
2923, 2852 (CH2 Str), 1648 (C‚O), 3293 (NH), 3031 (CH),
1562 (C‚N), 1029 (CAOAC). 1H NMR (300 MHz, CDCl3)
d ppm: 1.22–1.41 (m, 4H), 1.54–1.69 (m, 2H), 1.78–1.86 (m,
2H), 2.03–2.10 (m, 2H), 2.84–2.94 (m, 1H), 2.37 (s, 3H), 7.23
(t, 2H, J= 8.1 Hz), 7.43 (t, 1H, J= 8.1 Hz), 7.74 (d, 2H,
J= 8.1 Hz), 7.89–7.91 (m, 1H), 8.03 (t, 1H, J= 2.7 Hz),
8.18 (s, 1H). 13C NMR (400 MHz, CDCl3) d ppm 170.2, 166,
164.1, 142.6, 139, 131.6, 129.4, 127.2, 124.7, 123.1, 122.5,
120, 118.2, 35.2, 30.1, 27.3, 25.4, 21.5. LC/ESI-MS: m/z value;
362 (M+1).
2.5.4.6. N-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-2-
(2-fluoro-phenyl)acetamide (7c). Yield 67%, M.p 118. IR
(KBr, cm1); 2929, 2855 (CH2 Str), 1648 (C‚O), 3308
(NH), 3069 (CH), 1488 (C‚N), 1028 (CAOAC). 998 (CAF).
1H NMR (300 MHz, CDCl3) d ppm: 1.32–1.41 (m, 4H),
1.53–1.69 (m, 2H), 1.77–1.82 (m, 2H), 1.98–2.11 (m, 2H),
2.84–2.94 (m, 1H) 3.72 (s, 2H), 7.04–7.19 (m, 2H), 7.23–7.36
(m, 3H),7.40 (d, 2H, J= 6.3 Hz), 7.68–7.72 (m, 2H), 7.99 (s,
1H). 13C NMR (400 MHz, CDCl3) d ppm 170.2, 168.5,
164.1, 162.6, 159.3, 138.6, 131.6, 129.7, 127.6, 124.7, 122.9,
122.5, 121.4, 117.9, 111.5.8, 37.7, 35.3, 30.1, 29.7, 25.3, 25.3,
22.7. LC/ESI-MS: m/z value; 380 (M+1).
2.5.4.7. N-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-
3,5-difluoro-benzamide (7d). Yield 63%, M.p 110. IR (KBr,
cm1); 2927, 2857 (CH2 Str), 1660 (C‚O), 3323 (NH), 3028
(CH, Ar), 1471 (C‚N), 985 (CAOAC), 794 (Di fluoro). 1H
NMR (300 MHz, CDCl3) d ppm: 1.14–1.21 (m, 1H), 1.24–
1.38 (m, 3H), 1.50–1.65 (m, 2H), 1.76–1.78 (m, 2H), 1.98–
2.04 (m, 2H), 2.79–2.90 (m, 1H), 6.95 (td, 1H, J= 8.4 Hz),
7.37–7.43 (m, 2H), 7.45 (d, 1H, J= 8.1 Hz), 7.74 (d, 1H
J= 7.8 Hz), 7.96 (d, 1H, J= 8.2 Hz), 8.28 (s, 1H), 8.44 (s,
1H). 13C NMR (400 MHz, CDCl3) d ppm 170.3, 164.6,
164.1, 161.1, 138.6, 138, 129.7, 124.6, 123.8, 122.9, 119.0,
110.7, 107.2, 35.2, 30.1, 29.7, 25.3. LC/ESI-MS: m/z value;
384 (M+1).
2.5.4.8. Pyrazine-2-carboxylic acid [3-(5-cyclohexyl-[1,3,4]
oxadiazol-2-yl)-phenyl]-amide (7e). Yield 72%, M.p 138. IR
(KBr, cm1); 2928, 2853 (CH2 Str), 1682 (C‚O), 3320
(NH), 3056 (CH, Ar), 1470 (C‚N), 1020 (CAOAC). 1H
NMR (300 MHz, CDCl3) d ppm: 1.19–1.44 (m, 4H), 1.60–
1.70 (m, 2H), 1.79–1.83 (m, 2H), 2.07–2.12 (m, 2H), 2.88–
2.98 (m, 1H), 7.48 (t, 1H, J= 8.1 Hz), 7.81 (d, 1H,
J= 7.8 Hz), 7.97 (d, 1H, J= 8.1 Hz), 8.30 (s, 1H), 8.56 (s,
1H), 8.78 (d, 1H, J= 2.1 Hz), 9.47 (s, 1H), 9.77 (s, 1H). 13C
NMR (300 MHz, CDCl3) d ppm; 170.2, 163.9, 160.9, 147.8,
144.7, 144, 142.4, 137.9, 130, 125.1, 123.0, 122.5, 117.7, 35.3,
30.1, 25.4, 27.4. LC/ESI-MS: m/z value; 350 (M+1).iological evaluation of novel 2,5 substituted-1,3,4 oxadiazole derivatives. Saudi
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(1H-indol-3-yl)-acetamide (7f). Yield 78%, M.p 162. IR
(KBr, cm1); 2926, 2853 (CH2 Str), 1660 (C‚O), 3256 (NH 2
0-
Amide), 3086 (CH, Ar), 1566 (C‚N), 1038 (CAOAC). 1314
(NAN). 1H NMR (300 MHz, CDCl3) d ppm: 1.18–1.41 (m,
4H), 1.57–1.69 (m, 2H), 1.76–1.80 (m, 2H), 1.98–2.06 (d,
2H), 2.83–2.93 (m, 1H), 3.87 (s, 2H), 7.12 (t, 1H,
J= 7.2 Hz), 7.19–7.22 (m, 1H),7.31 (t, 1H, J= 8.1 Hz),7.39
(d,1H, J= 8.4 Hz), 7.54 (t, 2H, J= 7.8 Hz), 7.64 (dd, 2H,
J= 7.8 Hz), 7.80 (t, 1H, J= 1.8 Hz), 8.36 (s, 1H). 13C
NMR (300 MHz, CDCl3) d ppm 170.2, 164.1, 141.3, 138.4,
136.5, 129.6, 126.8, 124.5, 124.1, 122.9, 122.4, 120.3, 118.5,
117.8, 108.1, 102.8, 35.2, 34.5, 30.1, 29.7, 25.3. LC/ESI-MS:
m/z value; 431 (M+ 1).
2.5.4.10. Cyclopentane carboxylic acid [3-(5-cyclohexyl-
[1,3,4]oxadiazol-2-yl)-phenyl]-amide (7g). Yield 69%, M.p
144. IR (KBr, cm1); 2930, 2857 (CH2 Str), 1689 (C‚O),
3303 (NH), 3053 (CH, Ar), 1468 (C‚N), 995 (CAOAC). 1H
NMR (300 MHz, CDCl3) d ppm: 1.56–1.63 (m, 9H), 1.66–
1.98 (m, 9H), 2.61–2.71 (q, 1H), 2.85–2.95 (m, 1H), 7.37 (t,
2H, J= 7.8 Hz), 7.71 (t, 2H, J= 8.1 Hz), 8.11 (s, 1H). 13C
NMR (300 MHz, CDCl3) d ppm: 175.2, 170.1, 164.2, 139.2,
129.6, 124.6, 122.7, 122.7, 122.1, 117.8, 46.7, 35.3, 30.2, 26,
25.4, 22.4. LC/ESI-MS: m/z value; 340 (M+1).
2.5.4.11. Furan-2-carboxylic acid [3-(5-cyclohexyl-[1,3,4]oxa-
diazol-2-yl)-phenyl]-amide (7h). Yield 61%, M.p 121. IR
(KBr, cm1); 2927, 2857 (CH2 Str), 1660 (C‚O), 3323
(NH), 3028 (CH, Ar), 1471 (C‚N), 1005 (CAOAC). 1H
NMR (300 MHz, CDCl3) d ppm: 1.21–1.43 (m, 4H), 1.64–
1.70 (m, 2H), 1.78–1.84 (m, 2H), 2.06–2.10 (d, 2H), 2.87–
2.96 (m, 1H), 6.52 (dd, 1H, J= 3.6 Hz), 7.21 (t, 1H,
J= 3.6 Hz), 7.43 (t, 1H, J= 8.1 Hz), 7.48 (s, 1H), 7.77 (d,
1H, J= 7.8 Hz), 7.85 (d, 1H, J= 8.1 Hz), 7.97 (d, 1H,
J= 8.7 Hz), 8.16 (s, 1H), 8.19 (t, 1H, J= 1.8 Hz). 13C
NMR (300 MHz, CDCl3) d ppm 170.2, 164., 156.2, 147.4,
144.5, 138.1, 136.7, 129.8, 124.9, 122.7, 117.8, 115.7, 112.7,
35.3, 30.1, 29.6, 25.4. LC/ESI-MS: m/z value; 338 (M+1).
2.5.4.12. N-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-
3-furan-2-yl-acrylamide (7i). Yield 78%, mp 162, IR (KBr,
cm1): 2927, 2857 (CH2 Str), 1660 (C‚O), 3323 (NH), 3028
(CH, Ar), 1471 (C‚N), 989 (CAOAC). 1H NMR
(300 MHz, CDCl3) d ppm: 1.168–1.275 (m, 2H), 1.325–1.417
(m, 4H), 1.773–1.826 (m, 2H), 1.981–2.162 (d, 2H), 2.891–
2.979 (m, 1H), 6.413–6.442 (m, 1H), 6.492 (s, 1H), 6.55 (d,
1H, J= 3.3 Hz), 7.40 (t, 2H, J= 8.4 Hz), 7.52 (d, 1H,
J= 8.1 Hz), 7.70 (d, 1H, J= 7.8 Hz), 7.91 (d, 2H,
J= 8.1 Hz), 8.23 (s, 1H). 13C NMR (300 MHz, CDCl3) d
ppm; 169.2, 163.9, 163.5, 150.7, 143.4, 139.4, 128.7, 127.3,
123.7, 121.8, 120.8, 118.7, 116.9, 113.3, 111.6, 39.3, 34.4,
29.4, 24.5. LC/ESI-MS: m/z value; 364 (M+1).
2.5.4.13. N-[3-(5-Cyclohexyl-[1,3,4]oxadiazol-2-yl)-phenyl]-
4-methyl-benzenesulphonamide (8a). Yield 72%, mp 182, IR
(KBr, cm1): IR (KBr, cm1): 2921, 2849 (CH2 Str), 3430
(NH), 3053 (CH, Ar), 1471 (C‚N), 1158 (SO2 Str), 990
(CAOAC). 1H NMR (300 MHz, CDCl3) d ppm: 1.19–1.44
(m, 3H), 1.55–1.70 (m, 3H), 1.78–1.83 (m, 2H), 2.04–2.09
(dd, 2H), 2.28 (s, 3H), 2.90–3.0 (m, 1H), 7.16 (t, 2H,
J= 7.8 Hz), 7.28–7.37 (m, 2H), 7.54 (d, 1H, J= 5.1 Hz),Please cite this article in press as: Kavitha, S. et al., Synthesis, characterization and b
Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.07.0047.62 (d, 2H, J= 8.4 Hz), 7.87 (d, 1H, J= 1.5 Hz), 10.3 (s,
1H). 13C NMR (400 MHz, CDCl3) d ppm 170.6, 163.8,
143.8, 138.2, 136.2, 129.9, 129.7, 127.2, 124.9, 123.4, 122.6,
119.5, 35.3, 30.2, 27.4, 25.4, 21.5. LC/ESI-MS: m/z value;
398 (M+1).
2.5.4.14. 4-tert-Butyl-N-[3-(5-cyclohexyl-[1,3,4]oxadiazol-2-
yl)-phenyl]-benzenesulphonamide (8b). Yield 70%, mp 151,
IR (KBr, cm1); 2926, 2855 (CH2 Str), 3423 (NH), 3051
(CH, Ar), 1472 (C‚N), 1162 (SO2 Str), 983 (CAOAC),
1H
NMR (300 MHz, CDCl3) d ppm: 1.24–1.50 (m, 8H), 1.54–
1.68 (m, 5H), 1.73–1.77 (m, 3H), 2.01–2.05 (d, 3H), 2.97–
3.05 (m, 1H), 7.33–7.36 (m, 2H), 7.46 (t, 1H, J= 7.8 Hz),
7.72–7.78 (m, 4H), 7.85 (d, 1H, J= 8.7 Hz), 10.6 (s, 1H).
13C NMR (400 MHz, CDCl3) d ppm 169.1, 163.1, 156.1,
141, 138.8, 136.5, 130.4, 127.7, 126.2, 124.4, 118.9, 116.7, 39,
34, 31, 29.5, 25.1, 24.6. LC/ESI-MS: m/z value; 440 (M+1).
2.5.4.15. 3,5-Dichloro-N-[3-(5-cyclohexyl-[1,3,4]oxadiazol-2-
yl)-phenyl]-benzenesulphonamide (8c). Yield 76%, mp 176,
IR (KBr, cm1) 2924, 2853 (CH2 Str), 3440 (NH), 3050 (CH,
Ar), 1471 (C‚N), 1169 (SO2 Str), 939 (CAOAC),779 (CACl).
1H NMR (300 MHz, CDCl3) d ppm: 1.17–1.43 (m, 2H), 1.47–
1.52 (m, 2H), 1.60–1.69 (m, 2H), 1.74–1.91 (m, 2H), 2.02–2.06
(d, 2H), 2.98–3.07 (m, 1H),7.19–7.29 (m, 1H),7.32–7.39 (m,
2H),7.65 (t, 3H),7.75 (s, 1H), 11.0–11.3 (m, 1H) 13C NMR
(400 MHz, CDCl3) d ppm 169.6, 163, 142.5, 137.1, 134.3,
133.1, 131.7, 129.7, 124.5, 121.2, 117.9, 115.3, 40.1, 34.1, 29,
25.1. LC/ESI-MS: m/z value; 453 (M+1).
2.6. a-Amylase assay
Phosphate buffer saline (PBS, 0.02 mol/L, pH 6.8) was used to
dissolve the enzyme a-amylase at a concentration of 0.1 mg/
mL. Sample solutions having different concentrations
(0.25 mL) were mixed with the a-amylase solution (0.25 mL)
and incubated at 37 C for 5 min. The reaction mixture was
initiated by the addition of 0.5 mL 1.0% (w/v) starch substrate
solution to the incubation medium. After the elapsed time, the
reaction was stopped by adding 0.5 mL DNS reagent (1%
Dinitrosalicylic acid, 0.05% Na2SO3 and 1% NaOH solution)
and heated at 100 C for 5 min. Then the reaction mass is
cooled to room temperature. After cooling the absorbance
(Abs) at 540 nm was recorded using a spectrophotometer
(Balan et al., 2015; Tegginamath et al., 2011).
2.7. In vitro anti-inflammatory activity (Anti-denaturation
assay)
Newly synthesized fifteen compounds were evaluated for their
anti-inflammatory activity by albumin denaturation method.
The experiment was done by small modification (Priya et al.,
2011; Lavanya et al., 2015). The sample and standard were dis-
solved in minimum amount of DMF and diluted in phosphate
buffer (0.2 M, PH 7.4). Finally, DMF concentration in all
solutions was used less than 2.5%. 1 mL of 1 mM albumin
solution in phosphate buffer was mixed with test solution
(4 mL) containing different concentrations of drug and incu-
bated at 37 C for 15 min. The reaction mixture was Denatur-
ized by keeping at 70 C for 15 min. After cooling, the
turbidity was measured at 660 nm. Percentage of Inhibitioniological evaluation of novel 2,5 substituted-1,3,4 oxadiazole derivatives. Saudi
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was added. The diclofenac sodium was used as standard drug.
The percentage inhibition was calculated by using the follow-
ing empirical formula:
% of Inhibition ¼ 100 ðAtAcÞ=At
At ¼ O:D: of test solution Ac ¼ O:D: of control2.8. In vitro anticancer activity
The human cervical cancer cell lines (HeLa) were obtained
from National Centre for Cell Science (NCCS), Pune, and
grown in Eagles Minimum Essential Medium containing
10% foetal bovine serum (FBS). The cells were maintained
at 37 C, 5% CO2, 95% air and 100% relative humidity.
Maintenance cultures were passaged weekly, and the culture
medium was changed twice a week.
The monolayer cells were isolated with trypsin-ethylenedia
minetetraacetic acid (EDTA) to make single cell suspensions
and viable cells. Further, it was counted using a hemocytome-
ter, and diluted with medium containing 5% FBS to give the
final density of 1  105 cells/ml. One hundred microlitres per
well of cell suspension were seeded into 96-well plates, at the
density of 10,000 cells/well plates and incubated to the cell
attachment at 95% air, 37 C, 5% CO2, and 100% relative
humidity. After 24 h, the cells were treated with serial concen-
trations of the test samples. They were initially dissolved in
neat dimethylsulphoxide (DMSO), and an aliquot of the sam-
ple solution was diluted twice for maximum test concentration,
with serum-free medium. In addition, to those four serial dilu-
tions were made to provide a total of five sample concentra-
tions (6.25 lM, 12.5 lM, 25 lM, 50 lM, 100 lM). Aliquots
of 100 ll of these sample dilutions were added to the suitable
wells, which contains 100 ll of medium. After addition, the
plates were incubated for another 48 h at 37 C, 5% CO2,
95% air and 100% relative humidity. The medium containing
without samples was called as control and triplicate were main-
tained for all the concentrations.
After 48 h of incubation, 15 ll of MTT (5 mg/ml) in PBS
was added to all well and incubated at 37 C for 4 h. The med-
ium with MTT was then flicked off and the produced for-
mazan crystals were solubilized in 100 ll of DMSO and
measured the absorbance at 570 nm by microplate reader.
The % cell inhibition was determined using the following for-
mula (Monks et al., 1991):
% Cell Inhibition ¼ 100Abs ðsampleÞ=Abs ðcontrolÞ
 100:
Nonlinear regression graph was plotted between % Cell
inhibition and Log concentration and IC50 was determined
using Graph Pad Prism software.
3. Result and discussion
3.1. Chemistry
Benzohydrazide was refluxed with cyclohexanoic acid in the
presence of phosphorous oxychloride afforded 2-cyclohexyl-5
-phenyl-1,3,4-oxadiazole. Subsequently, it was carried out
nitration by KNO3/H2SO4, followed by reduction with tinPlease cite this article in press as: Kavitha, S. et al., Synthesis, characterization and b
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l) aniline. Furthermore, 3-(5-cyclohexyl-1,3,4-oxadiazol-2-yl)
aniline was used as key intermediate (6a-c), (7a-i), (8a-c)
respectively. All the newly synthesized compounds were char-
acterized by IR, NMR and Mass spectra and elemental
studies.
IR spectrum of compound 1 shows absorption band at
2933, 2855 cm1 due to the aliphatic stretching. An absorption
band at 1590 cm1 assignable for C‚N group and the region
at 1018 cm1 is due to stretching of oxadiazole ring. The
absence of peaks for hydrazide. So, it confirms the oxadiazole
formation. The IR Spectra of Compound 2 showed the peak at
1531 cm1 due to NO2. IR spectrum of Compound 3 showing
absorption peak at 3440 and 3362 cm1 due to the amine. IR
spectrum of compounds (6a-c) showed absorption bands at
around 3344, 3058, 2935, 1593, 1037 cm1 which were due to
the NA–H (amide), CAH (Aromatic), CH2 (Aliphatic),
C‚N, and CAOAC groups, respectively. The IR spectra of
oxadiazole derivatives (7a-i) showed peaks at region of
1646 cm1 due to C‚O and 3281 cm1 cm assignable for
NH. Similarly, IR spectrum of compounds (8a-c) exhibited
absorption bands at 2546 cm due to SO2 and peak at region
3355 cm1.
H1 NMR spectra of urea derivatives (6a-c) showed the
presence of two singlets appeared at around d 8.53–
8.73 ppm. The C13 NMR spectra of urea derivatives (6a-c)
indicated the presence of carbonyl group appeared at around
d 169.5 ppm. A signal at around 2.37 ppm was assigned to the
methylene proton. The singlet at around 3.72 and 3.83 ppm
was assigned to the methoxy and amino protons, respectively.
The peaks at around 30.1 and 55.2 ppm were assigned to the
methylene and methoxy carbon atoms. The H1 NMR spectra
of amide derivatives (7a-i) indicated the presence of one sin-
glet appeared at around 8.1 ppm for NH proton attached to
the carbonyl group. C13 NMR spectra revealed that the pres-
ence of carbonyl carbon showed at around d 170 ppm. Fur-
thermore, the H1 NMR spectrum of sulphonamide
derivatives (8a-c) showed broad downfield singlet appeared
at around d 10.64–11.25 ppm for sulphonamide NH proton.
The IR, 1H and C13 NMR and mass spectral data were found
in good agreement with the newly synthesized compounds (see
Fig. 1).
3.2. SAR studies
1. The anticancer activity results showed that the presence of
urea moiety with electron releasing group (methyl, meth-
oxy) may enhance cytotoxicity of the synthesized 1,3,4 oxa-
diazole derivatives. The electron releasing groups are
playing important role for improving anticancer activity
(Kumar et al., 2014).
2. The results also indicated that 1,3,4 oxadiazole ring
attached to the substituted benzene sulphonamide increased
cytotoxicity potential of tested compounds against MCF7
cell line, whereas, substituted benzamide unit attached to
1,3,4 oxadiazole derivatives decreased anticancer activity
against both MCF7 and He La cell lines.
3. SAR analysis indicated that presence of electron donating
groups on p-position of both urea and sulphonamide unit
with 1,3,4 oxadiazole ring may increase anti-inflammatory
and anticancer activity.iological evaluation of novel 2,5 substituted-1,3,4 oxadiazole derivatives. Saudi
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good activity against anti diabetic studies. Furthermore, 6f
showed high anti diabetic activity.
3.3. Antidiabetic activity
In the present study, it has been evaluated the inhibitory effects
of synthesized compounds against a-amylase activity. Synthe-
sized compounds were checked with five different concentra-
tions (50, 100, 250, 500, and 1000 lm) and acarbose was
used as a standard drug. The compounds (7f and 8c) showed
stronger inhibitory activity against a-amylase when compared
to the acarbose inhibitor, whereas, the compounds 6a, 6b, 7d,
7e, and 7g exhibited moderate activities and other the com-
pounds have exposed weak activity. The bar graph representa-
tion of antidiabetic activities of title compounds (6a-c, 7a-i,
and 8a-c) is shown in Fig. 2.
3.3. In-vitro Anti-inflammatory activity data
Anti-inflammatory activity was carried out by Serum albumin
denaturation method with four different concentrations such
as 50 lm, 100 lm, 300 lm, and 500 lm respectively. All the0 
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Figure 2 a-Amylase activity of synthesized compounds.
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their anti-inflammatory activity. Within series, Compounds
6a, 6c, and 8b having urea and sulphonamide unit showed
good activity, while, Compounds 6b, 7a, 7c, 7g, and 7i showed
moderate activity. Remaining compounds exhibited mild activ-
ity against the standard drug. The results of the anti-
inflammatory activity of the newly synthesized compounds
are shown in Fig. 3.
3.4. Anticancer activity
All newly synthesized 1,3,4-Oxadiazole derivatives were evalu-
ated for their anticancer activity towards two cell lines using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cis plastin was used as a standard drug. Anti-
cancer activities of all compounds were indicated by IC50 val-
ues and were calculated by linear regression analysis. Cisplatin
was used as a standard and among all the synthesized com-
pounds 6a, 6b, 6c, 7c, 7d, and 8b showed cytotoxicity on two
cell lines after 48 h exposures. The results showed that the
compounds 6b and 6c of 1,3,4 oxadiazole derivatives showed
significant activity against MCF-7 and HeLa cells. For these
compounds, IC50 values are in the range of 23.5–45.6 lM.0 
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Figure 5 In vitro anticancer screening of the Compounds 6a, 6b,
6c, 7c, 7d and 8b against MCF7 cell lines after 48 h exposure.
Table 1 Preliminary cytotoxicity screening and antidiabetic
activities of synthesized 1,3,4 oxadiazole derivatives.
Entry IC50 lM
HeLa MCF-7 Antidiabetic
6a 79.7 81.6 5.09
6b 30.4 23.5 5.29
6c 45.6 28.6 6.93
7a P100 P100 6.22
7b P100 P100 5.927
7c 80.1 78.3 6.510
7d 58.8 62.4 4.717
7e P100 P100 4.947
7f 100.3 P100 3.40
7g P100 P100 5.249
7h P100 P100 6.213
7i P100 P100 5.935
8a P100 P100 6.008
8b 62.9 60.9 5.561
8c P100 P100 3.268
Standard 3.5 3.5 2.09
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ity against both cell lines compared with the standard. From
the data, compound 6b may be the powerful anticancer agent
and the rest of other compounds did not show cytotoxic effects
on cell lines. The results of the anticancer activity of synthe-
sized compounds are shown in Figs. 4, 5 and Table 1.
4. Conclusion
A series of new 2,5-disubstituted 1,3,4-oxadiazole derivatives
bearing urea, amide, and sulphonamide were synthesized,
and their antidiabetic, anti-inflammatory, anticancer activities
were evaluated in vitro. The fifteen synthesized compounds
showed moderate to good activity against anti diabetic, anti-
inflammatory and anticancer activities. Among them, com-
pound 6b was found to be effective anticancer agents. The
antidiabetic activity of 7f and 8c was better than all other com-
pounds. The result revealed that introduction of urea and sul-
phonamide group in oxadiazole enhances activities. Based on
the above results, the current research is considered to synthe-
size 1,3,4 oxadiazole derivatives for their improvement of the
biological activity.
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